Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Net Margin: 2021-2025

Historic Net Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 12,011.34%.

  • Allogene Therapeutics' Net Margin fell 5315766.00% to 12,011.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 24,862.16%, marking a year-over-year decrease of 75950070.00%. This contributed to the annual value of -1,170,863.64% for FY2024, which is 82637416.00% down from last year.
  • Allogene Therapeutics' Net Margin amounted to 12,011.34% in Q3 2025, which was down 36.76% from 18,992.54% recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Net Margin peaked at 71,041.98% during Q4 2024, and registered a low of -375,447.62% during Q4 2023.
  • Moreover, its 3-year median value for Net Margin was -123,064.79% (2023), whereas its average is -139,008.37%.
  • In the last 5 years, Allogene Therapeutics' Net Margin plummeted by 36,014,866bps in 2022 and then surged by 44,648,959bps in 2024.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Net Margin stood at 2.50% in 2021, then plummeted by 36,014,866bps to -360,146.15% in 2022, then slumped by 1,530,147bps to -375,447.62% in 2023, then spiked by 44,648,959bps to 71,041.98% in 2024, then slumped by 5,315,766bps to 12,011.34% in 2025.
  • Its Net Margin stands at 12,011.34% for Q3 2025, versus 18,992.54% for Q2 2025 and 39,883.33% for Q1 2025.